Shao Su-Ju, Quan Chun-Fen, Shao Su-Xia, Zhou Miao, Jing Xin-Jian, Zhao Yu-Xiao, Ren Zhi-Xin, Wang Pei-Yu, Gao Xi-Yan, Yang Jie, Ren Zhong, Kong Li
Third Affiliated Hospital, Henan University of TCM, Zhengzhou 450003, China.
Zhongguo Zhen Jiu. 2013 Sep;33(9):774-8.
To evaluate the clinical efficacy of asthma at acute attack stage treated with "Shao's five needling therapy".
The randomized controlled method was applied to divide 210 cases into an observation group and a control group, 105 cases in each one. In the observation group, "Shao's five needling therapy" [Feishu (BL 13), Dazhui (GV 14), Fengmen (BL 12)] and the combined therapy were adopted, including oxygen uptake, aerosol inhalation and oral administration of prednisone. In the control group, the oral administration of theophylline sustained release tablet and the combined therapy were applied. The treatment was continued for 7 days. The clinical symptoms and physical signs such as wheezing, cough, expectoration, chest stuffiness, wheezing rale and shortness of breath, as well as lung function indices such as forced expiratory volume one second (FEV1) and peak expiratory flow (PEF) were observed before and after treatment in the two groups.
In the observation group, 69 cases were cured clinically, 20 cases effective remarkably, 7 cases effective and 0 case failed. In the control group, 49 cases were cured clinically, 31 cases effective remarkably, 15 cases effective and 0 case failed. The difference in the efficacy was significant in comparison of the two groups (P < 0.05). The therapeutic effect in the observation group was better than that in the control group. The total score of the symptoms and physical signs, FEV1 and PEF after treatment were all improved significantly in the two groups (all P < 0.01). And the results in the observation group were better than those in the control group (all P < 0.01).
"Shao's five needling therapy" achieves the significant efficacy on asthma at acute attack stage. It significantly relieves the symptoms and physical signs of the patients and improves lung functions. The effect is better than that of theophylline sustained release tablet.
评价“邵氏五针法”治疗哮喘急性发作期的临床疗效。
采用随机对照法将210例患者分为观察组和对照组,每组105例。观察组采用“邵氏五针法”[肺俞(BL 13)、大椎(GV 14)、风门(BL 12)]并结合吸氧、雾化吸入及口服泼尼松进行治疗。对照组采用口服茶碱缓释片并结合上述治疗方法。治疗持续7天。观察两组治疗前后的临床症状和体征,如喘息、咳嗽、咳痰、胸闷、哮鸣音及气短等,以及肺功能指标如一秒用力呼气容积(FEV1)和呼气峰值流速(PEF)。
观察组临床治愈69例,显效20例,有效7例,无效0例。对照组临床治愈49例,显效31例,有效15例,无效0例。两组疗效比较差异有统计学意义(P < 0.05)。观察组治疗效果优于对照组。两组治疗后症状和体征总分、FEV1及PEF均显著改善(均P < 0.01),且观察组结果优于对照组(均P < 0.01)。
“邵氏五针法”治疗哮喘急性发作期疗效显著,能明显缓解患者的症状和体征,改善肺功能,效果优于茶碱缓释片。